Pyxis Oncology, Inc.
PYXS
$1.84
-$1.53-45.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.77% | -6.09% | -549.82% | -128.06% | 8.01% |
| Total Depreciation and Amortization | -27.91% | -8.55% | -50.54% | -20.29% | 39.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 82.43% | 65.08% | -16.55% | 1,041.76% | -60.86% |
| Change in Net Operating Assets | 26.73% | -114.35% | 78.88% | -188.52% | 294.40% |
| Cash from Operations | 9.46% | -474.09% | -8.81% | -26.46% | 16.60% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 143,600.00% | 382,500.00% | 186.64% | 160.65% | 70.37% |
| Cash from Investing | 143,487.50% | 382,500.00% | 185.53% | 160.63% | -100.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -100.00% | -- | 645.95% |
| Repurchase of Common Stock | -700.00% | -55.81% | 98.98% | -14,611.54% | 99.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.48% | -160.91% | -100.00% | 300.00% | 1,067.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.07% | 29.97% | -136.68% | 246.84% | -16.41% |